Skip to main content
SRZN
NASDAQ Life Sciences

Major Investor Group, Including Director, Boosts Stake in Surrozen with $6M in Recent Stock Purchases

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$20.25
Mkt Cap
$171.386M
52W Low
$5.9
52W High
$24.94
52W Position info
243% above low
Off High info
19% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

SRZN has more than doubled off its 52-week low of $5.9.

Summary

A major institutional investor group, including a board director, reported approximately $6.0 million in recent stock purchases, significantly increasing their stake in Surrozen, Inc.


Key Events · Ownership and Investor Activity · SRZN

  • Significant Insider Buying

    The Column Group, a major institutional investor, reported approximately $6.0 million in stock purchases between November 2025 and January 2026.

  • Increased Beneficial Ownership

    The purchases, made by affiliated funds, represent a substantial increase in their stake, now totaling 35.1% of the company's common stock for individuals Tim Kutzkey (a director) and Peter Svennilson.

  • Director Confidence

    Tim Kutzkey, a member of Surrozen's board of directors, is part of the reporting group, signaling strong insider confidence.

  • Material Investment

    The aggregated purchases amount to approximately 3.5% of Surrozen's market capitalization, indicating a material commitment from a key investor.


Analysis · SRZN · Life Sciences

The Column Group, a significant institutional investor in Surrozen, Inc., along with its managing partners including board member Tim Kutzkey, has substantially increased its beneficial ownership through a series of stock purchases totaling approximately $6.0 million. These purchases, made between November 2025 and January 2026, represent a significant vote of confidence from a key long-term investor and director, indicating a strong belief in the company's future prospects. The aggregated purchases amount to approximately 3.5% of the company's current market capitalization, signaling a material increase in their commitment.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 52.1% of the 217 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SRZN was trading at $20.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.4M. The 52-week trading range was $5.90 to $24.94. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRZN - Latest Insights

SRZN
Nov 09, 2026, 4:59 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $32.64 info
Change: +$0.640 (+2%) info
Market Cap: $383.636M info
SRZN
Nov 09, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $32.64 info
Change: +$0.640 (+2%) info
Market Cap: $383.636M info
SRZN
Nov 09, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $32.64 info
Change: +$0.640 (+2%) info
Market Cap: $383.636M info
SRZN
Oct 20, 2026, 4:59 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $25.14
Real-time Price: $32.64 info
Change: +$7.50 (+30%) info
Market Cap: $383.636M info
SRZN
Oct 02, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.13
Real-time Price: $32.64 info
Change: +$2.51 (+8%) info
Market Cap: $383.636M info